What is BioSerenity?
Headquartered across Paris, France, and Atlanta, GA, USA, BioSerenity operates at the intersection of innovative medical technology and digital health. The company's core focus lies in providing comprehensive diagnostic solutions for healthcare providers and patients, with a geographical reach extending across the USA, Europe, and the Caribbean. BioSerenity has established itself as a preferred partner for Contract Research Organizations (CROs) and leading university medical facilities globally, leveraging its expertise in IoMT, AI, and real-world evidence to enhance patient care and clinical research outcomes in critical medical fields.
How much funding has BioSerenity raised?
BioSerenity has raised a total of $92.9M across 3 funding rounds:
Angel/Seed
$3.4M
Series A
$17.9M
Series B
$71.7M
Angel/Seed (2015): $3.4M with participation from Kurma Partners and IdInvest Partners
Series A (2017): $17.9M led by Idinvest Partners and LBO France
Series B (2019): $71.7M, investors not publicly disclosed
Key Investors in BioSerenity
Idinvest Partners
Idinvest Partners is a venture capital firm that finances and supports entrepreneurs at various stages of business development, with a focus on mid-market private equity. Founded in 1997 and based in Paris, France, they are known for their investment in innovative companies.
Kurma Partners
Kurma Partners is a European venture capital firm specializing in funding healthcare and biotechnology ventures from inception to expansion, with a focus on severe diseases and disruptive scientific discoveries.
What's next for BioSerenity?
The recent major strategic investment signals a new phase of accelerated growth and market expansion for BioSerenity. This capital infusion is expected to fuel further development of its AI-driven diagnostic platforms and IoMT solutions, particularly within its key focus areas of Neurology, Sleep Medicine, and Cardiology. The company's established relationships with CROs and academic institutions position it for significant advancements in real-world evidence generation, potentially solidifying its leadership in the Healthcare as a Service sector and driving innovation in patient care and clinical trials.
See full BioSerenity company page
